Biotechnology
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody
SUZHOU, China, June 9, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur ofShanghai, Chinese Academy of...
2020-06-10 08:40
5923
L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401, Featured at the 2020 Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO)
Treatment with LEAF-1401 exposes the tumor to 20-times more pentaglutamated pemetrexed than conventional pemetrexed. Polyglutamated pemetrexed has been shown to be 80-times more potent than pemetrexed in inhibiting thymidylate synthase (TS), a key enzyme in the folate pathway. Pemetrexed (Alimta®...
2020-06-10 03:15
1653
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer
SUZHOU, China, June 8, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) a clinical stage biopharmaceutical company focusing on innovative biologics medicine for oncology, and Sanofi (EURONEXT: SAN and NASDAQ: SNY), a global biopharmaceutical leader, announced today that Jiangsu Alpham...
2020-06-09 10:10
5828
Atomo and NG Biotech expand COVID-19 partnership: Atomo secures exclusive rights for Australia, New Zealand and South East Asia[1]
SYDNEY, June 9, 2020 /PRNewswire/ -- Atomo Diagnostics Limited (ASX: AT1) (Atomo ) is pleased to announce it has expanded its existing COVID-19 rapid test partnership with NG Biotech, SAS (NG Biotech), which was announced to ASX on 14 April 2020 in Atomo's Second Supplementary Prospectus (Second S...
2020-06-09 08:02
1315
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
CRANBURY, NJ and SHANGHAI, June 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has signed a 10-year lease for a clinical manufacturing facility (MFG18) inCranbury, New Jersey. The new clin...
2020-06-09 08:00
2215
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies
SUZHOU, China, June 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announ...
2020-06-09 07:30
5314
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies
SUZHOU, China, June 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announ...
2020-06-09 07:30
1834
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation
(Antengene) today announced its appointment of Mr.Donald Lung as Chief
Financial Officer (CFO), effectiveJune 8, 2020. Donald will report directly to
Dr.Jay Mei, Chairman and CEO of Antengene.
2020-06-08 20:00
2238
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...
2020-06-08 19:00
1824
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593),Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune r...
2020-06-05 13:00
2158
IPP Announces AGC Biologics Acquisition of AstraZeneca Boulder, CO Plant
PRINCETON JUNCTION, New Jersey, June 4, 2020 /PRNewswire/ -- International Process Plants (IPP), a global buyer and seller of pharmaceutical and biopharmaceutical manufacturing facilities and equipment, announced its client AGC Biologics' successful Q2/20 purchase of a state-of-the-art commercial...
2020-06-04 21:34
3029
Servier Completes the Acquisition of Symphogen
PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including oncology. ...
2020-06-04 21:30
2680
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
DAEJEON, South Korea, June 3, 2020 /PRNewswire/ -- PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the c...
2020-06-04 00:00
1524
Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine
AGC Biologics partners with Novavax to produce NVX-CoV2373 component SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner withNovavax, Inc. (NASDAQ: NVAX), a late-stage biot...
2020-06-03 19:00
3186
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need * A marketing application has now been accepted by the TGA under provisional evaluation pathway * Lurbinectedin has received priority review u...
2020-06-03 14:30
1459
Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment
FREIBURG, Germany, June 3, 2020 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the co...
2020-06-03 10:00
1684
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
SUZHOU, China, June 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces...
2020-06-03 07:30
6755
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 3, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-03 00:14
2611
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 2, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-02 23:41
1885
Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services
Tigermed's comprehensive service portfolio and robust infrastructure cement its status as a strategic partner for the pharmaceuticals industry LONDON, June 2, 2020 /PRNewswire/ -- Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recogniz...
2020-06-02 22:00
6668
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5187
